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One of the promises of nanoparticle (NP) carriers is the reformula-
tion of promising therapeutics that have failed clinical development
due to pharmacologic challenges. However, current nanomedicine
research has been focused on the delivery of established and novel
therapeutics. Here we demonstrate proof of the principle of using
NPs to revive the clinical potential of abandoned compounds using
wortmannin (Wtmn) as a model drug. Wtmn is a potent inhibitor of
phosphatidylinositol 3′ kinase-related kinases but failed clinical
translation due to drug-delivery challenges. We engineered a NP
formulation of Wtmn and demonstrated that NP Wtmn has higher
solubility and lower toxicity compared withWtmn. To establish the
clinical translation potential of NP Wtmn, we evaluated the thera-
peutic as a radiosensitizer in vitro and in vivo. NP Wtmn was found
to be a potent radiosensitizer and was significantly more effective
than the commonly used radiosensitizer cisplatin in vitro in three
cancer cell lines. The mechanism of action of NP Wtmn radiosensiti-
zation was found to be through the inhibition of DNA-dependent
protein kinase phosphorylation. Finally, NPWtmnwas shown to be
an effective radiosensitizer in vivo using two murine xenograft
models of cancer. Our results demonstrate that NP drug-delivery
systems can promote the readoption of abandoned drugs such as
Wtmn by overcoming drug-delivery challenges.
nanotechnology | nanoparticle radiosensitizer
Nanoparticles (NPs) possess unique properties, such as pref-erential accumulation in tumors and reduced distribution in
normal tissue, that make them ideally suited for the treatment of
cancer. Consequently, there has been high interest in developing
NP-based therapeutics for cancer treatment (1). Current research
has been focused on developing NP formulations of widely used
chemotherapeutics or newly discovered cancer agents, which are
few in number (2). However, one of the promises and great
potentials of NP drug-delivery carriers is the reformulation of
abandoned cancer therapeutics that were initially promising but
failed clinical development due to challenges in delivery. Although
these challenges are difficult to overcome with traditional drug-
delivery techniques, NP drug-delivery vehicles present an un-
precedented opportunity. In this study, we aim to demonstrate
proof of principle that NPs permit the reformulation of abandoned
therapeutics into formulations appropriate for clinical use.
We used wortmannin (Wtmn) as a model drug for our study.
Wtmn is a furanosteroid metabolite of the fungi Penicillium funi-
culosum and Talaromyces (Penicillium) wortmannii (3). It is an
inhibitor of phosphatidylinositol 3′ kinases (PI3Ks) and phospha-
tidylinositol 3′ kinase-related kinases (PIKKs) such as DNA-
dependent protein kinase (DNA-PK) (4). Although preclinical
studies showedWtmn was an extremely effective radiosensitizer, its
clinical translation was limited by poor solubility, low stability, and
high toxicity (3–8). Since its discovery more than four decades ago,
many Wtmn analogs have been developed to improve on the sta-
bility and pharmacologic properties of Wtmn (9–11). Today, only
one Wtmn analog, PX-866, remains under clinical investigation
(12). Wtmn is now a commonly used laboratory research reagent
for the inhibition of class I PI3Ks (13).
Because NP drug delivery has the ability to overcome poor
solubility, low stability, and high toxicity, we hypothesized that NP
formulation of Wtmn can renew the clinical translation potential
of Wtmn. In this study, we report the development of a polymeric
NP formulation of Wtmn. We demonstrated that NP formulation
has improved Wtmn’s solubility, stability, and toxicity. NP Wtmn
was shown to be a potent radiosensitizer in vitro and in vivo. Our
study demonstrates that NP drug delivery can renew the clinical
potential of abandoned therapeutics and that such strategy can
emerge as a paradigm in drug development.
Results
NP Wtmn Characterization. A NP formulation of Wtmn was de-
veloped using a biodegradable lipid-polymer NP platform (14, 15).
These NPs contain a hydrophobic polymeric core and a lipid-
polymer surface. The NP is stabilized by a monolayer of lipids
(lecithin and the PEGylated lipids [1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-amino(polyethylene glycol) (DSPE-PEG)]
(Fig. 1A). The polyethylene glycol (PEG) surface prevents serum
protein adsorption. The solvent ratios and Wtmn:polymer ratio
were optimized to achieve maximum Wtmn loading. A loading
efficiency of 20% (wt/wt) was achieved, and the maximum loading
attained was 4% of Wtmn by weight. Dynamic light scattering
analysis revealed that the NP Wtmn possesses a narrow size dis-
tribution with polydispersity of 0.15 ± 0.03. These results were
confirmed by transmission electron microscopy (TEM) analysis,
which showed monodispersed NPs with a well-defined spherical
shape and an average size of 40 nm (Fig. 1B). ζ-Potential analysis
demonstrated that the NPs possess a negatively charged surface
of −38 ± 5 mV.
Wtmn has a very low solubility of 4 mg/L in aqueous solutions.
In comparison, the solubility of the NPWtmn was 20 g/L.We were
able to dissolve 20 mg of NP Wtmn (containing 4% Wtmn by
weight) in 1 mL of saline, equivalent to 800 mg/L of Wtmn. This
represents a 200-fold increase in free Wtmn solubility. Mass
spectrometry illustrated that Wtmn does not react with compo-
nents of the NP. High-performance liquid chromatography
(HPLC) confirmed the release of intact Wtmn from the NPs. Fig.
1C shows the percentage of Wtmn released over a period of 24 h.
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Drug release studies revealed that NP Wtmn releases Wtmn in
a controlled fashion.
NP Wtmn Has Significantly Lower Toxicity than Wtmn. A major lim-
itation of Wtmn as a cancer therapeutic is its toxicity (16). We
hypothesized that NP formulation of Wtmn would significantly
reduce Wtmn toxicity. As a control we solubilized Wtmn with
cremophor, a well-established solvent for poorly soluble chemo-
therapeutics. From this point on in this article, “Wtmn” refers to
the cremophor formulation of Wtmn unless otherwise specified.
Given that toxicity evaluations can depend on the mouse strain,
themaximum tolerated dose (MTD) of both NPWtmn andWtmn
was determined in four strains of mice (NOD/SCID, C57BL/6,
CB6F1, and CD1). As seen in Table 1, the MTD for NP Wtmn is
three to five times higher than that of Wtmn. This indicates that
the NP Wtmn has a three- to five-times lower overall toxicity
profile compared with that of Wtmn. Furthermore, hepatotoxicity
and hematologic toxicities (17), the dose-limiting toxicities of
Wtmn, were compared between NP Wtmn and Wtmn. Because
the MTD was similar between the mouse strains, we chose to
evaluate these toxicities in CD1 mice only. The toxicities were
compared at 1/5th and 1/10th of the Wtmn MTD. As shown in
Table 2, mice treated with 0.14 mg/kg of Wtmn had a depressed
granulocyte count of 0.8 ± 0.14 (103/μL) [normal 1.2–8 (103/μL)]
and significantly elevated alanine transaminase (ALT) levels of
134 ± 17 U/L (normal 40–50 U/L). In comparison, mice treated
with 7 mg/kg NPWtmn (which contains 0.14 mg/kg of Wtmn) had
granulocyte counts of 2.9 ± 0.07 (103/μL) and slightly elevated
ALT levels at 82 ± 12 U/L. At 1/10th MTD dose, we did not ob-
serve any significant hepatotoxicity or hematologic toxicities.
In Vitro Evaluation of NP Wtmn as a Radiosensitizer. Unlike small
molecules that permeate through the cell membrane, NPs enter
cells through endocytosis. Therefore, NP Wtmn may have a ther-
apeutic efficacy and/or mechanism of action different from that of
Wtmn. Thus, we evaluated NP Wtmn as a radiosensitizer in vitro
in three tumor-cell lines representing three different cancers: KB
(head and neck cancer), PC-3 (prostate cancer), and HT-29 (co-
lorectal cancer). NPWtmn andWtmnwere found to haveminimal
cytotoxicity in these cells at concentrations lower than 10 μM (Fig.
2A). Radiation survival curves comparing NPWtmn toWtmn and
cisplatin, one of the most common clinical radiosensitizers,
showed that NP Wtmn is a potent radiosensitizer and is more
effective than cisplatin (P = 0.05) (Fig. 2B). Furthermore, NP
Wtmn eliminated the “shoulder region” of the survival curves. A
shorter therapeutic incubation time of 1 h was also evaluated, and
the clonogenic survival curves were similar to that of the 3-h in-
cubation (Fig. S1).
The potency of a radiosensitizer can be quantified by the sen-
sitizer enhancement ratio (SER) (18). As shown in Table S2, the
SER of NPWtmn is 3.68 and is similar to that of 3.51 forWtmn in
KB cells at 10% survival. In all three tumor-cell lines, the SER of
NP Wtmn is nearly double that of the SER of cisplatin. These
results indicate that NP Wtmn is a very potent radiosensitizer
in vitro.
NP Wtmn Sensitizes Cancer Cells to Radiotherapy by Inhibiting DNA-
PK.Wtmn is known to inhibit phosphorylation of Akt (p-Akt) (19).
To determine if the mechanism of action of NPWtmn is similar to
Wtmn, p-Akt levels were determined in KB cells. As seen in Fig. 3,
the level of p-Akt was increased in cells that received radiotherapy
(XRT). In contrast, cells incubated with either NPWtmn orWtmn
followed by radiotherapy had low levels of p-Akt until 24 h post
Fig. 1. Characterization of NP Wtmn. (A) Cartoon of NP Wtmn depicting
a PLGA core containing Wtmn surrounded by a lipid monolayer (green head
groups) and a PEG shell. (B) TEM image of NP Wtmn. (C) Release profile of
NP Wtmn in PBS at 37 °C. Error bars correspond to SD of three separate
sample preparations with duplicate samples per data point.
Table 1. MTD of Wtmn formulations in four different strains
of mice
Wtmn NP Wtmn
Mouse strain MTD (mg/kg) MTD (mg/kg)
NOD/SCID 0.7 2.2 (110)
C57BL/6 (Black) 0.7 2.4 (120)
CB6F1 (Brown) 0.5 2.5 (125)
CD1 (White) 0.7 2.4 (120)
Numbers represent milligrams per kilograms of Wtmn, either in cremo-
phor solution or encapsulated in NP (2% wt/wt). Numbers in parentheses
represent milligrams per kilograms of the NP Wtmn including the weight of
the NP.
Table 2. Toxicity profile in CD1 mice post i.v. injection of Wtmn
formulations
Normal range Wtmn NP Wtmn
1/5th MTD of Wtmn (0.14 mg/kg)
Hematologic toxicity
WBC 3.5–10 (103/μL) 2.8 ± 0.28 5.1 ± 0.42
Granulocytes 1.2–8 (103/μL) 0.8 ± 0.14 2.9 ± 0.07
Lymphocytes 0.5–5 (103/μL) 0.4 ± 0.42 3.56 ± 0.21
Monocytes 0.1–1.5 (103/μL) 0.55 ± 0.07 0.7 ± 0.14
Hepatotoxicity
ALT U/L 40–50 U/L 134 ± 17 82 ± 12
AST U/L 40–50 U/L 44 ± 3 46 ± 7
1/10th MTD of Wtmn (0.07 mg/kg)
Hematologic toxicity
WBC 3.5–10 (103/μL) 4.3 ± 0.13 4.9 ± 0.20
Granulocytes 1.2–8 (103/μL) 2.4 ± 0.11 3.7 ± 0.12
Lymphocytes 0.5–5 (103/μL) 0.9 ± 0.28 1.05 ± 0.21
Monocytes 0.1–1.5 (103/μL) 0.8 ± 0.42 0.5 ± 0.14
Hepatotoxicity
ALT U/L 40–50 U/L 64 ± 11 60 ± 9
AST U/L 40–50 U/L 40 ± 7 42 ± 10
Micewere treatedwith indicated doses ofWtmnorNPWtmn containing an
equivalent dose of Wtmn (2% wt/wt). Single tail-vein i.v. injection was given,
and a toxicity profile was taken 24 h post injection. Full profile is in Table S1.


















drug treatment. This demonstrates that NP Wtmn functions sim-
ilarly to Wtmn with respect to inhibition of Akt phosphorylation.
Wtmn’s proposed mechanism of function as a radiosensitizer is
the inhibition of radiation-induced autophosphorylation of DNA-
PKcs (DNA-dependent protein kinase catalytic subunit) (5, 6). To
validate NPWtmn function as a radiosensitizer through inhibition
of DNA-PKcs, we used the M059K (DNA-PK intact) and M059J
(DNA-PK deficient) glioblastoma-derived cell lines (20). Fig. 4A
shows that M059K cells treated with either Wtmn or NP Wtmn
had survival curves similar to that of M059J cells. On the other
hand, neither NP Wtmn nor Wtmn could sensitize the DNA-PK–
deficientM059J further to radiotherapy. These results suggest that
themechanism of action for NPWtmn radiosensitization is indeed
through inhibition of DNA-PKcs. We further confirmed the
findings by examining the phosphorylated DNA-PKcs (p-DNA-
PKcs) levels in irradiated M059K cells. As seen in Fig. 4B, un-
treated M059K cells demonstrated increased levels of p-DNA-
PKcs after radiotherapy, whereas cells first treated with NPWtmn
or Wtmn and then irradiated showed only a moderate increase
in p-DNA-PKcs.
In Vivo Evaluation of NP Wtmn as a Radiosensitizer. To evaluate the
potential clinical translation of NP Wtmn as a radiosensitizer, we
studied its radiosensitization efficacy in vivo using a murine xe-
nograft model of cancer. Immune-deficient NOD/SCID mice
bearing KB cell xenografts were treated with a single dose of
Wtmn or NP Wtmn followed by radiotherapy, and the tumor
volume was measured (Fig. 5A). Mice that received Wtmn or NP
Wtmn with no radiotherapy had similar tumor growth rates to that
of mice that received no treatment, indicating that Wtmn and NP
Wtmn alone had minimal effects. In comparison, mice treated
withWtmn or NPWtmn plus radiotherapy had significant delay in
tumor growth, indicating excellent radiosensitization effects.
When the tumor growth delay curves were compared between
mice receiving NP Wtmn and Wtmn, the difference in delay was
found to be statistically significant (P< 0.01). Histological samples
from the tumors post treatment revealed a decrease in nuclear
staining of p-DNA-PKcs from NP Wtmn-treated mice compared
with tumors from mice that received only radiotherapy (Fig. 5B).
This further validates the mechanism of action of NP Wtmn
in vivo. We confirmed the in vivo findings using mice bearing HT-
29 tumor-cell xenografts. NP Wtmn was compared with 5-flur-
ouracil (5-FU), a commonly used radiosensitizer in chemo-
radiotherapy for gastrointestinal cancers. Using three times the
initial tumor volume as an end point, we generated survival curves
and showed that NP Wtmn is an effective radiosensitizer and is
more effective than 5-FU (P < 0.05) (Fig. S2A). Tumor growth
curves also demonstrated that NP Wtmn is significantly more ef-
fective as a radiosensitizer than 5-FU (P < 0.02) (Fig. S2B).
Fig. 2. In vitro efficacy of NP Wtmn. (A) Dose–response assay to measure cytotoxicity of NP Wtmn and Wtmn in three cancer cell lines: KB (head and neck
cancer cell line), PC-3 (prostate cancer cell line), and HT-29 (colon cancer cell line). Cells were treated with indicated doses of Wtmn or NP Wtmn containing an
equivalent dose of Wtmn. Cells were also treated with vehicle controls cremophor or empty NP. (B) Clonogenic assay of cancer cell lines after treatment with
25 μM Wtmn or NP Wtmn (containing 25 μM Wtmn) and radiation. Error bars correspond to the SD of repeated measurements (two NP preparations, du-
plicate measurements per preparation per data point). Wtmn + radiation and NP Wtmn + radiation curves are significantly different from cisplatin + radiation
(P = 0.05) and radiation only (P = 0.05) curves.
Fig. 3. Effect of Wtmn formulations and radiation on phosphorylation of
Akt. KB cells were pretreated with 25 μM Wtmn or NP Wtmn (containing 25
μM Wtmn) for 3 h and subsequently irradiated (4 Gy). Cell lysates were
collected at indicated time points.
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Discussion
Before the development of NP drug-delivery vehicles, the strat-
egy to overcome pharmacologic challenges of a promising small-
molecule therapeutic was the modification of molecular struc-
tures. However, these modifications frequently led to diminished
therapeutic efficacy and increased toxicity. As a result, many
promising therapeutics failed clinical translation due to drug-
delivery challenges and are no longer considered clinically viable.
Wtmn is one such example. First discovered four decades ago,
it was highly promising as a chemotherapeutic and a radio-
sensitizer. Unfortunately, its poor solubility, low stability, and
high toxicity prevented its clinical translation. Many analogs of
Wtmn have been formulated since its discovery, but none have
succeeded thus far. The development of NP drug-delivery vehi-
cles is a disruptive technology that has the potential to renew the
clinical potential of “abandoned” drugs like Wtmn. Therefore,
we aimed to demonstrate the proof-of-principle of this approach
using Wtmn as a model drug.
An NP formulation of Wtmn was developed using a bio-
degradable polymeric NP platform. Wtmn is a highly hydrophobic
molecule, and as a result the hydrophobic polymeric core of NPs
can easily encapsulateWtmn and, at the same time, protect it from
environmental degradation. We found that Wtmn is unreactive
with the NP and is released from the NP in a controlled fashion.
We also showed that NP Wtmn is highly soluble in saline. Thus,
NP delivery of Wtmn indirectly improved the stability and solu-
bility of Wtmn by protecting it from an aqueous environment.
Characterization ofNPWtmn’s physical properties showed that its
size and surface charge are generally considered excellent for
in vivo cancer applications (21). Although the NPs were able to
encapsulate only 4% (wt/wt) of Wtmn, this loading capacity was
determined to be more than sufficient for potential clinical
applications due to the high potency of Wtmn.
One of the major barriers to the clinical translation of Wtmn is
its systemic toxicity. Our data showed that NP Wtmn’s MTD is
three to five times higher than that of Wtmn, indicating a signif-
icantly lower toxicity profile for NP Wtmn. In a detailed analysis
of the dose-limiting hepatotoxicity and hematologic toxicities, NP
Wtmn was found to have fewer toxic effects on the liver and bone
marrow than Wtmn. Together, these results show that the NP
formulation of Wtmn has dramatically reduced Wtmn’s toxicities
and renewed the potential for its clinical translation.
Wtmn’s greatest therapeutic potential lies in its ability to po-
tentiate the effects of radiotherapy.Wtmn inhibits DNA-PK, a key
protein involved in the repair of double-stranded DNA damage.
Because double-stranded DNA damage is the principal mecha-
nism of action for radiotherapy, Wtmn has been determined to be
a highly potent radiosensitizer. Furthermore, improving the
therapeutic index of radiotherapy has been a major research focus
in oncology (22–25). Our in vitro radiosensitization results dem-
onstrated that NPWtmn is a potent radiosensitizer. Furthermore,
it is able to reduce the “shoulder region” in the radiation survival
curves. The elimination of the shoulder region is highly significant,
as daily clinical radiotherapy doses (1.5–3 Gy) generally fall into
the shoulder region. The shoulder region, which reflects less ef-
fective cell killing by radiotherapy, is thought to be caused by the
ability of tumor cells to repair their double-stranded DNA dam-
age. Most radiosensitizers, like cisplatin, shifted the cell survival
curves downward but did not reduce the shoulder region. In
contrast, NP Wtmn not only shifted the cell survival curves
downward, but also eliminated the shoulder region. Because the
difference between cell survival is compounded each day as clin-
ical radiotherapy is generally administered daily for several weeks,
improved therapeutic efficacy in the shoulder region can lead to
a potentially dramatic clinical treatment benefit. As an example, in
themore radiosensitive HT-29 cell line, a single fraction of 2 Gy of
radiotherapy with NP Wtmn is equivalent to approximately three
fractions of 2 Gy of radiotherapy alone or two fractions of 2 Gy of
radiotherapy with cisplatin (Fig. S3). However, in a radioresistant
cell line like KB, a single fraction of 2 Gy of radiotherapy with NP
Wtmn is equivalent to approximately 26 fractions of 2 Gy of ra-
diotherapy alone or three fractions of 2 Gy of radiotherapy with
cisplatin. Another method to assess radiosensitization efficacy is
Fig. 4. NP Wtmn inhibits DNA-PK phosphorylation. (A) Effect of Wtmn for-
mulations and radiation on DNA-PK phosphorylation. Clonogenic assay with
glioma cancer cell lines M059K (DNA-PKcs positive) and M059J (DNA-PKcs
negative) after treatment with Wtmn formulations and radiation. Error bars
correspond to SD of repeated measurements (two nanoparticle preparations,
duplicatemeasurementsper preparationper datapoint). (B)M059KandM059J
cells were pretreated with 25 μMWtmn or NPWtmn for 3 h and subsequently
irradiated (4 Gy). Cell lysates were collected at the indicated time points.
Fig. 5. In vivo efficacy of NP Wtmn. (A) Tumor growth inhibition efficacy of
Wtmn formulations on s.c. tumor xenograft. Mice received single tail-vein
i.v. injections of 0.07 mg/kg of Wtmn or 3.5 mg/kg of NP Wtmn (contains the
equivalent dose of 0.07 mg/kg Wtmn). Tumors were radiated locally once 3 h
post injection (6 Gy). (B) pDNA-PKcs immunohistochemistry of untreated,
irradiated only, or NP Wtmn and irradiated tumors collected 24 h post
treatment. Nuclei are stained with hematoxylin.


















through the SER. Effective clinical radiosensitizers have SERs of
nearly 2 at 10% cell survival. SERs of 3 or greater have been shown
in vitro for very potent radiosensitizers, including Wtmn, but have
never been translated into clinical practice (18). NP Wtmn was
able to achieve a SER of 2.7–3.7 in this study. Together, the re-
duction in the shoulder region and the increase in the SER
demonstrate NP Wtmn to be a potent radiosensitizer with very
high therapeutic potential.
We confirmed that the NP Wtmn’s mechanism of action is the
same asWtmn. BothAkt andDNA-PK are involved in the cellular
response to DNA damage and are phosphorylated as a result of
radiotherapy (5, 6, 19, 26). Our results clearly demonstrated that
no phosphorylation of either Akt or DNA-PK ensued in cancer
cells incubated with NP Wtmn or Wtmn plus radiation. The sim-
ilarity in the response confirms that the NP formulation of Wtmn
does not alter the mechanism of action of Wtmn.
To demonstrate the therapeutic potential of NP Wtmn in vivo,
murine xenograft models of cancer were used. Our study used
a low dose of radiotherapy (6 Gy) and low doses of Wtmn and
NP Wtmn (0.07 mg/kg of Wtmn). Our results demonstrated that
NP Wtmn is indeed a powerful radiosensitizer. The fact that NP
Wtmn is significantly more effective than Wtmn supports the
hypothesis that the NP formulation has both improved Wtmn’s
efficacy and reduced its toxicity. Histological studies confirmed
that the mechanism of radiosensitization in vivo is through
DNA-PK inhibition.
In conclusion, we report the development of a NP formulation
of Wtmn and demonstrate its potential as a radiosensitizer. NP
Wtmn was found to be soluble and stable, and it possesses sig-
nificantly lower toxicity than Wtmn. We also showed that NP
Wtmn is a highly effective radiosensitizer, both in vitro and in vivo,
even at doses significantly below MTD. Our study demonstrates
the potential for clinical use of NP Wtmn that employs a NP
therapeutic carrier to renew the clinical translation potential of an
“abandoned” drug. This illustrates that abandoned therapeutics,
such as Wtmn, can be brought into the clinic with NP for-
mulations. Our work also addresses, at least in part, some of the
major barriers to bringing otherwise promising small molecules
from the laboratory to the clinic. Most importantly, this strategy
can be applied to many other therapeutics that have the potential
to impact the treatment of many human diseases in addition
to cancer, the clinical translation of which has been hindered
by toxicity.
Materials and Methods
Materials.Wtmnwas purchased from Sigma-Aldrich and LC Laboratories. Poly
(D,L-lactide-coglycolide) (PLGA) with a 50:50 monomer ratio, ester-termi-
nated, and viscosity of 0.72–0.92 dL/g was purchased from Durect. Soybean
lecithin consisting of 90–95% (wt/wt) phosphatidylcholine was obtained
from MP Biomedicals. DSPE–PEG2000–COOH [1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-carboxy (polyethylene glycol) 2000] was obtained
from Avanti Polar Lipids.
Formulation and Characterization of NP Wtmn. PLGA–lecithin–PEG core–shell
NPs were synthesized from PLGA, soybean lecithin, and DSPE–PEG–COOH
using a previously reported nanoprecipitation technique (14). Wtmn was
dissolved at a dosage of 10% (wt/wt) of the polymer into the PLGA/aceto-
nitrile solution (1 mg/mL) before nanoprecipitation. NP size (diameter in
nm), polydispersity, and surface charge (ζ-potential in mV) were obtained
with a ZetaPALS dynamic light-scattering detector (Brookhaven Instru-
ments). TEM images were obtained at the Microscopy Services Laboratory
Core Facility at the University of North Carolina School of Medicine.
Nanoparticle Wtmn Release. Three-milliliter NP solutions at a concentration of
0.5 mg/mL were split equally into 30 Slide-ALyzer MINI dialysis microtubes
with a molecular weight cutoff of 10 kDa (Pierce) and subjected to dialysis
against 4 L phosphate buffer saline (PBS) with gentle stirring at 37 °C. PBS was
changed periodically during the dialysis process. At the indicated times, 0.2
mL of solution from two microtubes was removed and mixed with an equal
volume of acetonitrile to dissolve the NPs. Wtmn content was subjected to
quantitative analysis using an Agilent 1100 HPLC equipped with a C18 chro-
molith flash column (Merck KGaA). Wtmn concentration was measured using
the Ultraviolet/Visible detector at 245 nm. Wtmn retention time was 1.6 min
in 50:50 acetonitrile/water nongradient mobile phase at 0.25 mL/min.
Cell Culture. Cancer cell lines KB, HT-29, PC3, M059J, and M059K were
obtained from ATCC. KB cells were cultured in Eagle’s Minimum Essential
Medium supplemented with 10% (vol/vol) FBS (Mediatech) and penicillin/
streptomycin (Mediatech). PC3 and HT29 were cultured in a 1:1 mixture of
DMEM and Ham’s F-12 medium (Gibco, Invitrogen) supplemented with 10%
(vol/vol) FBS and penicillin/streptomycin. M059J and M059K were maintained
in a 1:1 mixture of DMEM and Ham’s F-12 medium supplemented with 0.05
mM nonessential amino acids, penicillin/streptomycin, and 10% FBS.
Cell Viability Assay. Cells were plated on 96-well plates at a density of 30,000
cells per well. NP Wtmn, free Wtmn (dissolved in cremophor), NP, and cre-
mophor were added to cells in a total final volume of 0.1 mL per well and
were incubated for 3 h. At the end of incubation, cells were gently washed
twice with sterile PBS and were further incubated with sterile fresh complete
medium for 48 h at 37 °C and 5% CO2. To evaluate cell viability, cells were
washed with sterile PBS, and an MTS [(3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)] assay was performed
according to manufacturer’s instructions (Promega).
Clonogenic Survival Assay. Cells (2 × 106) were seeded in 4 mL of culture
medium in 25-mL flasks before treatment. Cells were treated with thera-
peutics for 3 h and washed two times with sterile PBS after incubation. Cells
were trypsinized and seeded at various densities ranging from 100 to
100,000 cells in 4 mL of culture medium in 25-mL flasks and radiated with 0,
2, 4, 6, and 8 Gy from an X-RAD 320 (Precision X-Ray) machine operating at
320 kVp and 12.5 mA. The dose rate at a source-subject distance of 50 cm
was 2.07 Gy/min. Cells were incubated for 12 d after irradiation and then
fixed in 1:1 acetone/methanol and stained with trypan blue. All colonies
with over 50 cells were counted. The relative cell-surviving fraction was
calculated by dividing the number of colonies of radiated cells by the cells
plated, with a correction for the plating efficiency.
Western Blot. Cells were treated with 25 μM Wtmn, NP Wtmn, or vehicle for
3 h, washed with PBS, and incubated with fresh media before 4 Gy irradi-
ation. Cell lysates were collected in HNTG (20 mM Hepes; 150 mM NaCl; 10%
glycerol; 0.1% Triton-X100; 1mM Na3VO4) buffer at the indicated times post
irradiation. Protein concentration was measured by bicinchoninic acid pro-
tein assay (Pierce). Primary antibodies used were Akt (Cell Signaling), p-Akt
(Ser473) (Cell Signaling), DNA PKcs (Abcam), DNA-PKcs (phospho S2056)
(Abcam), and β-actin (13E5) (Cell Signaling) at dilutions indicated by the
manufacturers. Secondary antibodies were α-mouse IgG HRP-linked anti-
body (Cell Signaling) or α-rabbit IgG HRP-linked antibody (Cell Signaling).
MTD. MTD—defined as the highest possible dose resulting in no animal
deaths and less than 20% weight loss—was evaluated for Wtmn for-
mulations. Non-tumor–bearing mice (NOD/SCID, C57BL/6, CB6F1, and CD1)
(Charles River Laboratories) were injected with varying amounts of NP Wtmn
and Wtmn normalized to milligram of Wtmn injected/kilogram of mice body
weight. The animals were weighed and observed daily for any change in
physical activity.
Mice were housed in an American Association for the Accreditation of
Laboratory Animal Care-accredited facility in sterile housing at the Univer-
sity of North Carolina at Chapel Hill, and the work was approved and
monitored by the University of North Carolina Animal Care and Use
Committee.
Toxicity. CD1 mice were given tail-vein i.v. injection with different Wtmn
formulations (NP Wtmn or Wtmn in cremophor) at the indicated doses (1/5th
the MTD or 1/10th the MTD). After 24 h, submandibular bleeding was per-
formed. Blood (100–200 μL) was collected in heparin-coated tubes to prevent
coagulation. Whole-blood samples were immediately submitted for blood
toxicity to the Animal Clinical Laboratory Core Facility at the University of
North Carolina. For liver toxicity studies, blood samples were centrifuged
(15,000 × g for 10 min) to separate blood cells from the plasma, and samples
were submitted for analysis.
Tumor Efficacy. KB cells (1 × 106 cells in 200 μL 1:1 RPMI-1640 and matrigel)
were s.c. inoculated into the left flank of 6- to 8-wk-old male NOD/SCID
mice. Ten days after inoculation, the mice were randomly distributed into
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different groups for subsequent treatment. We aimed to achieve tumor
volume of 50–75 mm3. NP Wtmn (3.5 mg/kg) or free Wtmn in cremophor
formulation (0.07 mg/kg) was tail-vein i.v. injected. The dose of NP Wtmn
contains an equivalent of 0.07 mg/kg of Wtmn. Three hours post injection,
the tumors were subjected to a dose of 6 Gy with XRAD 320. Mice were
shielded with a specially designed lead shield allowing radiation of the tu-
mor site and minimal radiation to other organs. Tumor volumes were cal-
culated by measuring two perpendicular diameters with a caliper and by
using the formula of V = 0.5 × a × b2 where, a and b are the larger and
smaller diameters, respectively. The tumor volumes were measured every
2–4 d, and the relative percentage change in tumor volume was calculated
using the relation 100 * (Vi − Vo)/Vo, where Vi is the volume calculated and
Vo is the initial volume on day 1.
HT-29 cells (1 × 106 cells in 200 μL 1:1 RPMI-1640 and matrigel) were s.c.
inoculated into the upper dorsal region of 6- to 8 wk-old male Nu/Nu mice.
Ten days after inoculation, mice were randomly distributed into different
groups for subsequent treatment. Average tumor volume before treatment
was ∼200 mm3. NP Wtmn (3.5 mg/kg) or 5-flurouracil (25 mg/kg) was tail-
vein i.v. injected. Three hours post injection, tumors were subjected to
a dose of 6 Gy with XRAD 320. Mice were shielded with a specially designed
lead shield allowing radiation of the tumor site and minimal radiation to
other organs. Tumor volumes were calculated as above. The change in tu-
mor volume was monitored by taking the ratio Vi/Vo, where Vi is the volume
calculated and Vo is the volume on day 0. Tumor growth for the different
treatment modalities was monitored until this ratio value reached 3, at
which point the animals were euthanized.
Tumor Histology. KB cells (1 × 106 cells in 200 μL 1:1 RPMI-1640 and matrigel)
were s.c. inoculated into left flank of 6- to 8-wk-old male NOD/SCID mice.
Ten days after inoculation, mice were given treatments. Twenty-four hours
post irradiation, animals were euthanized and tumors were removed and
fixed in 10% neutral buffered formalin (vol/vol) (Thermo Scientific). Immu-
nohistochemistry was performed on paraffin-embedded sections of tumor
using DNA-PKcs (phospho S2056) (Abcam) and hematoxylin.
Statistics. To statistically compare the in vitro clonogenic assays, we chose the
area under the growth curve (AUC).Wilcoxon rank sum testwas performed to
compare the survival fraction of the different groups. The exact one-sided
P value of the Wilcoxon rank sum test is presented.
To statistically compare the percentage change inKB tumor growth rates of
Wtmn + XRT and NP Wtmn + XRT-treated mice, we chose the AUC over the
largest commonobservation period as an indicator of growth rate. The largest
common observation period of the two groups is from time 0 to day 76. We
used the trapezoidal rule to approximate AUC. On the basis of the AUCs, the
Wilcoxon rank sum test was performed to compare the growth rates between
the two groups. The exact one-sided P value of the Wilcoxon rank sum test is
presented. To statistically compare the change in HT-29 tumor growth rates
of Wtmn + XRT and 5-flurouracil + XRT-treated mice, we recorded the time
needed for the tumors to reach three times the initial volume and generated
a Kaplan–Meier curve. One-sided P value of the Wilcoxon rank sum test is
presented. Also, AUC was measured as above to compare the change in tu-
mor growth for d 0–12.
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